Q4 Earnings Forecast for WVE Issued By HC Wainwright

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at HC Wainwright issued their Q4 2027 earnings estimates for shares of WAVE Life Sciences in a note issued to investors on Wednesday, October 28th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.12) per share.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The business had revenue of $13.16 million during the quarter, compared to analysts’ expectations of $4.51 million.

Several other equities analysts have also recently issued reports on the company. Zacks Research cut WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Mizuho decreased their price objective on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Citigroup lowered their target price on WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. B. Riley Financial lowered their target price on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.89.

WAVE Life Sciences Stock Performance

Shares of WVE opened at $3.64 on Thursday. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73. The firm has a 50-day simple moving average of $4.13 and a 200-day simple moving average of $7.60. The company has a market capitalization of $717.92 million, a price-to-earnings ratio of -3.34 and a beta of -1.43.

Insider Buying and Selling at WAVE Life Sciences

In other news, Director Adrian Rawcliffe sold 12,700 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director directly owned 44,930 shares in the company, valued at approximately $270,029.30. The trade was a 13.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 23,564 shares of company stock valued at $132,476 in the last 90 days. Company insiders own 24.34% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences in the 2nd quarter valued at approximately $27,465,000. Squarepoint Ops LLC increased its position in WAVE Life Sciences by 68.0% during the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after purchasing an additional 1,029,052 shares during the period. Pictet Asset Management Holding SA raised its stake in shares of WAVE Life Sciences by 42.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after buying an additional 343,226 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after buying an additional 360,800 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of WAVE Life Sciences by 12.4% in the 1st quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock valued at $2,619,000 after buying an additional 39,759 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33–$0.34 analyst consensus. Revenue of $13.16 million also substantially exceeded estimates of approximately $4.51 million, helping ease concerns about the company’s near-term financial performance. Wave Life Sciences Stock Rallies as Q3 Results Ease Loss Fears
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, providing a meaningful future catalyst if the program continues to generate positive data. WAVE Life Sciences Reports Third Quarter Results and Business Update
• Positive Sentiment: Management’s earnings call and business update provided investors with additional detail on the development pipeline and upcoming clinical milestones, supporting optimism around WVE-006 and the company’s broader RNA-editing platform. WAVE Life Sciences Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Oppenheimer reduced its price target to $29 from $32 but maintained an Outperform rating. The lower target is a modest valuation reset, while the unchanged rating indicates the analyst remains constructive on WVE’s long-term prospects. Oppenheimer Adjusts WAVE Life Sciences Price Target
• Negative Sentiment: Despite the earnings beat, WAVE remains unprofitable, reporting a quarterly loss and maintaining substantial cash-burn risk as it funds clinical development. Analysts continue to forecast a full-year loss, leaving the stock highly dependent on future trial progress and financing conditions. WAVE Life Sciences Reports Q3 Loss and Tops Revenue Estimates

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.